以及如何将这些行动传达给更广泛的利益相关者。IRWG包括直接参与国际科技公司,政府和民间社会代表的事件响应工作各个方面的专家。The Handbook is divided into sections reviewing considerations and best practices related to (1) communication during an incident response, (2) qualitative metrics, (3) quantitative metrics to track during an incident for transparency reporting, (4) human rights due diligence indicators, (5) potential implications, metrics, and considerations around bystander footage, and (6) virality of content in and around a violent extremist or terrorist incident.这六个主题构成了手册的六个部分。所有工作组输出均可在GIFCT工作组页面上提供。
“RESOLVED THAT pursuant to Sections 196, 197, 203, and other applicable provisions, if any, of the Companies Act, 2013 read with Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, as amended from time to time made thereunder (including any statutory modification(s) or re- enactment thereof for the time being in force) read with Schedule V to the Act and pursuant to Regulation 17 (1C) and other 2015年SEBI(上市义务和披露要求)法规的适用法规以及其他规定适用于适用的规定,并按照公司的提名和薪酬委员会在2023年3月18日举行的会议上的提名和薪酬委员会的建议,并在2023年3月18日的会议上批准了该公司董事会的批准。 Pathanjali(DIN:05297665)担任公司董事总经理,从2023年4月1日到
“RESOLVED THAT pursuant to the provisions of Sections 139, 141, 142 and other applicable provisions, if any, of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014, and the Guidelines for Appointment of Statutory Central Auditors (SCAs)/Statutory Auditors (SAs) of Commercial Banks (excluding RRBs), UCBs and NBFCs (including HFCS)由印度储备银行(“ RBI”)发行。RBI/2021-22/25-参考。编号dos.co.arg/sec.01/01/08.91.001/2021-22 2021年4月27日,包括任何修正,修改或变化,M/s Bilimoria Mehta&Co。该公司在2027年举行的第109届年度股东大会的结论,但要按照其连续性履行适用的资格规范,并在此类薪酬上,这是公司董事会与联合法定审计师之间的共同商定的。
“RESOLVED THAT pursuant to the provisions of Sections 149,150,152 and other applicable provisions, if any, of the Companies Act, 2013(“the Act”) read with Schedule IV to the Act (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force) and the Companies (Appointment and Qualification of Directors) Rules, 2014, as amended to date, and Regulations 16(1)(b)印度证券交易委员会(上市义务和披露要求)条例,2015年(“法规”),迄今为止修订,并根据提名与薪酬委员会的建议和董事会的建议和董事会的建议,Akhilesh Agarwal先生(Akhilesh Agarwal先生)(Akhilesh Agarwal先生)(DIN:00918888888),以宣布为宣布的诉讼,该组织宣布了该宣告的行为,该公司的公认是该宣告的一致。第149(6)条第16(1)(b)条
(c) The Secretary of the Interior and the Governor of the Common- wealth of the Northern Mariana Islands shall each submit a report to the Committee on Interior and Insular Affairs of the House of Representatives and the Committee on Energy and Natural Re- sources of the Senate on any efforts to develop any needed modifica- tion of the income tax rates required by sections 601 and 602 of the Covenant to Establish a Commonwealth of the Northern Mariana Islands in Political Union由美国公法94-241证明的美国(90 Stat。263,269-270)执行此类部分。最初的报告应不晚于1984年1月1日发行,此后随后的报告每三个月发送到1985年1月1日。报告应阐明联邦政府和政府的确切目标,任何差异领域,所考虑的修改以及解决任何差异的方面,并实施了第601和602节的规定。
This document contains two sections comprising of: Part A – Capacity Summary for Ireland 2022-2031 - This outlines the purpose of the Generation Capacity Statement (GCS), the main messages from the GCS and the impact of the mitigation measures which are being progressed under the Commission for Regulation of Utilities (CRU) Security of Supply Work Programme supported by the Department of the Environment, Climate and Communications and EirGrid.B部分 - 生成能力声明2022-2031-这是一份全岛文件,是对EIRGRID的监管要求和SONI的许可要求。根据SONI许可要求,这一代能力声明已由北爱尔兰的公用事业监管机构批准。包含GCS中所有表和数字的数据工作簿将与本文档一起单独发布。
在临床研究中参与合并症的受试者中观察到的Vaxigriptetra的安全性与在整体人群中观察到的受试者没有差异。此外,在肾移植患者中对Vaxigrip进行的研究,哮喘患者在这些人群中Vaxigrip的安全性方面没有显着差异。在南非和马里孕妇进行的临床研究中使用Vaxigrip进行的孕妇(请参阅第4.6和5.1节),在疫苗给药后7天内报道的本地和全身性征求反应的频率与vaxigrip进行临床研究期间成人人群报道的疫苗一致。 在南非的研究中,Vaxigrip组的局部反应比在HIV阴性和HIV阳性队列中的安慰剂组中更频繁。 在两个队列中,Vaxigrip和安慰剂组之间的征求反应没有其他显着差异。 In one clinical study conducted in pregnant women in Finland with VaxigripTetra (see sections 4.6 and 5.1), frequencies of local and systemic solicited reactions reported within 7 days following administration of VaxigripTetra were consistent with those reported for the adult population (with the exception of pregnant women) during clinical studies conducted with VaxigripTetra even though higher for some adverse reactions (injection site pain, malaise, shivering, headache,肌痛)。使用Vaxigrip进行的孕妇(请参阅第4.6和5.1节),在疫苗给药后7天内报道的本地和全身性征求反应的频率与vaxigrip进行临床研究期间成人人群报道的疫苗一致。在南非的研究中,Vaxigrip组的局部反应比在HIV阴性和HIV阳性队列中的安慰剂组中更频繁。 在两个队列中,Vaxigrip和安慰剂组之间的征求反应没有其他显着差异。 In one clinical study conducted in pregnant women in Finland with VaxigripTetra (see sections 4.6 and 5.1), frequencies of local and systemic solicited reactions reported within 7 days following administration of VaxigripTetra were consistent with those reported for the adult population (with the exception of pregnant women) during clinical studies conducted with VaxigripTetra even though higher for some adverse reactions (injection site pain, malaise, shivering, headache,肌痛)。在南非的研究中,Vaxigrip组的局部反应比在HIV阴性和HIV阳性队列中的安慰剂组中更频繁。在两个队列中,Vaxigrip和安慰剂组之间的征求反应没有其他显着差异。In one clinical study conducted in pregnant women in Finland with VaxigripTetra (see sections 4.6 and 5.1), frequencies of local and systemic solicited reactions reported within 7 days following administration of VaxigripTetra were consistent with those reported for the adult population (with the exception of pregnant women) during clinical studies conducted with VaxigripTetra even though higher for some adverse reactions (injection site pain, malaise, shivering, headache,肌痛)。
在最初发表的文章的版本中,在图。4,“ 1.5 h”已被校正为“ 1.2 h”和Refs。71和72不正确,现在已修改为:Waters Corporation。MS成像 - Select Series™Maldi和MRT。www.waters.com/webassets/ cms/library/docs/720007652en.pdf(2022)和oetjen,J。等。新型的MALDI成像解决方案由flex和专用生物信息学管道赋予了赋予的能力,用于鉴定来自组织的脂质。https://www.bruker.com/en/applications/academia-life-science/imaging/maldi-imaging/maldi-imaging/patialomx/_jcr_content/ root/sections/section_1751684075/sectionpar/sectionpar/sectionpar/sectionpar/ search.download-asset.pdf/10b76c66666666666666666666666666666661f5937c336ee/1869079-lcms-156- maldi-Imaging-by-by-by-timstof-flex-ebook-ebook-ebook-ebook-rev-rev-rev-rev-01.pdf(2019)。这些校正已对本文的HTML和PDF版本进行了反映,也反映在补充数据1。
实际结果与此类陈述所表示或暗示的结果有重大不同。不能保证临床研究成功的管道产品,这些产品将获得必要的监管批准,或者证明它们将在商业上取得成功。如果基本假设证明不准确,风险或不确定性实现,则实际结果可能与前瞻性陈述所规定的或暗示的结果有重大差异。Additional information regarding these and other factors can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in our subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov和www.pfizer.com。
原始文件(1987 年 6 月)由现场气象数据工作组准备,该工作组成立于 1985 年 12 月,由 EPA-OAQPS 的 Roger Brode 担任主席。其成员及其贡献如下:Edward Bennett,纽约州 DEC,第 6.6 节;Roger Brode,EPA-OAQPS,第 1.0、2.0 和 4.0 节;James Dicke,EPA-OAQPS,第 5.2 节;Robert Eskridge,EPA-ASRL,第 6.2 和 6.3 节;Mark Garrison,EPA-Region III,第 3.2 和 9.0 节;John Irwin,EPA-ASRL,第 6.1 和 6.4 节;Michael Koerber,EPA-Region V,第 3.1 和 3.3 节;Thomas Lockhart,气象标准研究所,第 8.0 节; Timothy 方法,EPA-Region V,第 3.4 节;Stephen Perkins,EPA-Region I,第 6.5 和 7.0 节;以及 Robert Wilson,EPA-Region 10,第 5.1 和 8.6 节以及第 8.1、8.2 和 8.5 节的部分内容。通过内部审查和讨论,所有工作组成员都为整个文件的形成做出了贡献。工作组希望感谢 EPA 内部和外部为该文件提供技术审查意见的人员所付出的时间和努力。工作组还感谢 Joseph A. Tikvart(EPA-OAQPS)的支持和有益指导。